You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
|
|---|---|
| Published in |
Journal of Hematology & Oncology, January 2017
|
| DOI | 10.1186/s13045-016-0379-6 |
| Pubmed ID | |
| Authors |
Erhao Zhang, Hanmei Xu |
| Abstract |
Adoptive cell therapy using chimeric antigen receptor (CAR)-engineered T cells has emerged as a very promising approach to combating cancer. Despite its ability to eliminate tumors shown in some clinical trials, CAR-T cell therapy involves some significant safety challenges, such as cytokine release syndrome (CRS) and "on-target, off-tumor" toxicity, which is related to poor control of the dose, location, and timing of T cell activity. In the past few years, some strategies to avoid the side effects of CAR-T cell therapy have been reported, including suicide gene, inhibitory CAR, dual-antigen receptor, and the use of exogenous molecules as switches to control the CAR-T cell functions. Because of the advances of the CAR paradigm and other forms of cancer immunotherapy, the most effective means of defeating the cancer has become the integration therapy with the combinatorial control system of switchable dual-receptor CAR-T cell and immune checkpoint blockade. |
Mendeley readers
The data shown below were compiled from readership statistics for 203 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Japan | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 200 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 36 | 18% |
| Student > Ph. D. Student | 33 | 16% |
| Student > Master | 28 | 14% |
| Researcher | 26 | 13% |
| Student > Doctoral Student | 13 | 6% |
| Other | 23 | 11% |
| Unknown | 44 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 44 | 22% |
| Agricultural and Biological Sciences | 30 | 15% |
| Medicine and Dentistry | 28 | 14% |
| Immunology and Microbiology | 22 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 4% |
| Other | 19 | 9% |
| Unknown | 52 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2023.
All research outputs
#3,318,010
of 23,043,346 outputs
Outputs from Journal of Hematology & Oncology
#263
of 1,198 outputs
Outputs of similar age
#69,826
of 421,933 outputs
Outputs of similar age from Journal of Hematology & Oncology
#6
of 38 outputs
Altmetric has tracked 23,043,346 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,198 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.4. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 421,933 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.